Author: OurCrowd

[SignalRank in SignalRank] White Paper: Enhancing Series B Investment Outcomes

Sep 30, 2024 |

In the highly competitive venture capital landscape, identifying high-potential Series B investments is crucial for maximizing returns. Traditional methods often fall short in navigating the complexities and dynamic nature of these investments, the market is too complex and large for a human to map everything going on in VC. SignalRank offers a data-driven dual approach with both heuristic algorithms and machine learning algorithms, combining expert knowledge with machine intelligence to optimize investment outcomes. Read...

Read More

[Biolojic in Biolojic Target Review] Unlocking the potential of smart antibodies

Sep 30, 2024 |

Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment. These differentiated programs have the potential to provide better clinical outcomes than existing treatments. Read...

Read More